Atea Pharmaceuticals Presents Initail Phase 2 Results for Bemnifosbuvir And Ruzasvir Mix In Treating Hepatitis C At The 2024 EASL Congress

6/5/24 7:54:45 AM ET

$AVIR

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AVIR alert in real time by email

97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study
EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barrier to Resistance

Get the next $AVIR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVIR

Date	Price Target	Rating	Analyst
8/13/2024	$2.00 → $6.88	Underweight → Equal-Weight	Morgan Stanley
8/10/2023		Neutral → Underweight	JP Morgan
3/2/2022	$10.00 → $8.00	Neutral	JP Morgan
3/1/2022	$10.00 → $9.00	Market Perform	SVB Leerink
2/16/2022	$11.00 → $10.00	Market Perform	SVB Leerink
1/6/2022	$14.00 → $7.00	Equal-Weight → Underweight	Morgan Stanley
11/18/2021		Outperform → Mkt Perform	SVB Leerink
11/18/2021	$11.00	Outperform → Market Perform	SVB Leerink

More analyst ratings

$AVIR
Financials

Live finance-specific insights

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases' (AASLD's) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended Septem
11/7/24 4:05:00 PM ET
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir
10/31/24 7:00:00 AM ET
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q'24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral Potency, Low Risk of Drug Interaction, Short Treatment Duration and High Barrier to Resistance Results from COVID-19 Global Phase 3 SUNRISE-3 Trial Expected 2H'24 Conference Call at 4:30 pm ET Today BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial resul
8/7/24 4:05:00 PM ET
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for the treatment of HCV. These data are being presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from Novembe
11/15/24 11:00:00 AM ET
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases' (AASLD's) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended Septem
11/7/24 4:05:00 PM ET
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir
10/31/24 7:00:00 AM ET
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care

$AVIR
Leadership Updates

Live Leadership Updates

Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Dr. Agrawal previously served as Vice President of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism at Merck & Co., Inc. "We are delighted to welcome Nancy to the Atea team. Her broad scientific and managerial experience in both drug discovery and drug development spanning across multiple therapeutic areas at Merck, will enrich our scientific and c
2/10/22 7:00:00 AM ET
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care
Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs
BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Dr. Avila previously served as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19 at Gilead Sciences. "We are very pleased to welcome Claudio to the Atea team. Claudio's extensive expertise and experience in medical affairs with a focus on COVID-19, hepatitis and HIV as part of his overall interest in serious viral infectious diseases, will complement and s
6/15/21 7:00:00 AM ET
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care
Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors
BOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors. Dr. Adams most recently served as Surgeon General of the United States and brings a wide range of experience spanning clinical practice, clinical research, public health, and government agency leadership. "We are honored to welcome Dr. Adams to our Board of Directors, as his unique experience as Surgeon General during the COVID-19 pandemic will undoubtedly help guide Atea as we continue to advance our ant
5/20/21 7:00:00 AM ET
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care

Atea Pharmaceuticals Presents Initail Phase 2 Results for Bemnifosbuvir And Ruzasvir Mix In Treating Hepatitis C At The 2024 EASL Congress

Chat with this insight

Recent Analyst Ratings for $AVIR

$AVIR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President, CEO, and Chairman Sommadossi Jean-Pierre sold $234,155 worth of shares (57,969 units at $4.04) (SEC Form 4)

SEC Form 4 filed by Director Duncan Barbara Gayle

SEC Form 4 filed by Director Berger Franklin M

$AVIR Financials

Live finance-specific insights

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

$AVIR SEC Filings

SEC Form EFFECT filed by Atea Pharmaceuticals Inc.

SEC Form S-3 filed by Atea Pharmaceuticals Inc.

SEC Form 10-Q filed by Atea Pharmaceuticals Inc.

$AVIR Market Insights

Live Market Insights

Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus

Atea Pharmaceuticals Presents Initail Phase 2 Results for Bemnifosbuvir And Ruzasvir Mix In Treating Hepatitis C At The 2024 EASL Congress

Atea Pharmaceuticals Announced It Will Presents New Data Showcasing Potential Best-in-class Combination Profile Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus At EASL Congress 2024

$AVIR Press Releases

Fastest customizable press release news feed in the world

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

$AVIR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

$AVIR Leadership Updates

Live Leadership Updates

Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs

Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors

$AVIR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Atea Pharmaceuticals upgraded by Morgan Stanley with a new price target

Atea Pharmaceuticals downgraded by JP Morgan

JP Morgan reiterated coverage on Atea Pharmaceuticals with a new price target

Recent Analyst Ratings for
$AVIR

$AVIR
Insider Trading

$AVIR
Financials

$AVIR
SEC Filings

$AVIR
Market Insights

$AVIR
Press Releases

$AVIR
Large Ownership Changes

$AVIR
Leadership Updates

$AVIR
Analyst Ratings